Renal Function after Major Uro-Oncologic Surgery and Dexmedetomidine Infusion


Objective: Acute kidney injury in major surgery is associated with increased postoperative mortality. This study aimed to evaluate renal function after major urologic surgery and intraoperative dexmedetomidine infusion. Methods: Thirty oncologic patients with normal renal function scheduled for prostatectomy or nephrectomy, anesthetized with combined epidural and general anesthesia, were randomized to receive either intraoperative blind infusion of dexmedetomidine (Dexmedetomidine Group, n = 15, 0.5 μg/kg load dose plus 0.7 μg/kg/h) or 0.9% saline (Control Group, n = 15) until the end of surgery. Intraoperative and cumulative 24-hour diuresis, serum creatinine (SCr), calculated creatinine clearance (ClCr) and serum cystatin C (SCys) at postoperative days 1, 2 and 3 and 2 weeks after surgery were evaluated. Results: Mean ± standard deviation values for intraoperative diuresis in Dexmedetomidine and Control Groups were 566 ± 396 mL and 298 ± 153 mL, respectively (p = 0.014). Cumulative 24-hour diuresis in Dexmedetomidine and Control Groups was 1947 ± 266 mL and 1748 ± 237 mL, respectively (p = 0.91). Mean values of SCr, ClCr and SCys were not significantly different from their baseline values in both groups and no significant differences were seen between groups at any moment for two weeks (p > 0.05). Conclusion: According to the doses used in this study, despite an intraoperative increase in diuresis, intraoperative infusion of dexmedetomidine did not influence renal performance up to two weeks after major uro-oncologic surgery, as evaluated by SCr, ClCr and SCys.

Share and Cite:

M. M. Novaes, P. G. Lavinas, G. D. Pires, A. G. de Carvalho, R. B. Lopes, R. El Dib and P. Nascimento Jr., "Renal Function after Major Uro-Oncologic Surgery and Dexmedetomidine Infusion," Open Journal of Anesthesiology, Vol. 3 No. 8, 2013, pp. 356-362. doi: 10.4236/ojanes.2013.38076.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] D. R. Jones and H. T. Lee, “Perioperative Renal Protection,” Best Practice & Research Clinical Anaesthesiology, Vol. 22, No. 1, 2008, pp. 193-208.
[2] G. M. Chertow, E. Burdick, M. Honour, J. V. Bonventre and D. W. Bates, “Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients,” Journal of the American Society of Nephrology, Vol. 16, No. 11, 2005, pp. 3365-3370.
[3] R. N. Sladen, “Anesthetic Considerations for the Patient with Renal Failure,” Anesthesiology Clinics of North America, Vol. 18, No. 4, 2000, pp. 863-882.
[4] A. Cho, J. E. Lee, G. Y. Kwon, W. Huh, H. M. Lee, Y. G. Kim, D. J. Kim, H. Y. Oh and H. Y. Choi, “Post-Operative Acute Kidney Injury in Patients with Renal Cell Carcinoma Is a Potent Risk Factor for New-Onset Chronic Kidney Disease after Radical Nephrectomy,” Nephrology Dialysis Transplantation, Vol. 26, No. 11, 2011, pp. 3496-3501.
[5] R. Venkataraman and J. A. Kellum, “Prevention of Acute Renal Failure,” Chest, Vol. 131, No. 1, 2007, pp. 300-308.
[6] J. E. Hall, T. D. Uhrich, J. A. Barney, S. R. Arain and T. J. Ebert, “Sedative, Amnestic, and Analgesic Properties of Small-Dose Dexmedetomidine Infusions,” Anesthesia & Analgesia, Vol. 90, No. 3, 2000, pp. 699-705.
[7] K. Leino, M. Hynynen, J. Jalonen, M. Salmenpera, H. Scheinin and R. Aantaa, “Renal Effects of Dexmedetomidine during Coronary Artery Bypass Surgery: A Randomized Placebo-Controlled Study,” BMC Anesthesiology, Vol. 11, 2011, p. 9.
[8] A. Bekker and M. K. Sturaitis, “Dexmedetomidine for Neurological Surgery,” Neurosurgery, Vol. 57, No. 1, 2005, pp. 1-10.
[9] A. Bayram, A. Esmaoglu, A. Akin, G. Baskol, R. Aksu, C. Bicer, A. Demirtas, R. Mutluay and A. Boyaci, “The Effects of Intraoperative Infusion of Dexmedetomidine on Early Renal Function after Percutaneous Nephrolithotomy,” Acta Anaesthesiologica Scandinavica, Vol. 55, No. 5, 2011, pp. 539-544.
[10] D. W. Cockcroft and M. H. Gault, “Prediction of Creatinine Clearance from Serum Creatinine,” Nephron, Vol. 16, No. 1, 1976, pp. 31-41.
[11] R. J. Frumento, H. G. Logginidou, S. Wahlander, G. Wagener, H. R. Playford and R. N. Sladen, “Dexmedetomidine Infusion Is Associated with Enhanced Renal Function after Thoracic Surgery,” Journal of Clinical Anesthesia, Vol. 18, No. 6, 2006, pp. 422-426.
[12] P. Shenoy, P. Ward and T. Wigmore, “Surgical Management of Urological Malignancy: Anaesthetic and Critical Care Considerations,” Current Anaesthesia & Critical Care, Vol. 20, No. 1, 2009, pp. 22-27.
[13] Y. Xu and B. Wu, “Prognostic Factors for Renal Dysfunction after Nephrectomy in Renal Cell Carcinomas,” Journal of Surgical Research, Vol. 166, No. 1, 2011, pp. e53-e57.
[14] A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch and C. Y. Hsu, “Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization,” The New England Journal of Medicine, Vol. 351, No. 13, 2004, pp. 1296-1305.
[15] S. A. Josephs and C. V. Thakar, “Perioperative Risk Assessment, Prevention, and Treatment of Acute Kidney Injury,” International Anesthesiology Clinics, Vol. 47, No. 4, 2009, pp. 89-105.
[16] P. Talke, C. A. Richardson, M. Scheinin and D. M. Fisher, “Postoperative Pharmacokinetics and Sympatholytic Effects of Dexmedetomidine,” Anesthesia & Analgesia, Vol. 85, No. 5, 1997, pp. 1136-1142.
[17] F. G. Curtis, Y. M. Castiglia, A. A. Stolf, E. Ronzella, S. M. Vanni and P. Nascimento Junior, “Dexmedetomidine and Sufentanil as Intraoperative Analgesics: Comparative Study,” Revista Brasileira de Anestesiologia, Vol. 52, No. 5, 2002, pp. 525-534.
[18] R. M. Venn, C. J. Bradshaw, R. Spencer, D. Brealey, E. Caudwell, C. Naughton, A. Vedio, M. Singer, R. Feneck, D. Treacher, S. M. Willatts and R. M. Grounds, “Preliminary UK Experience of Dexmedetomidine, a Novel Agent for Postoperative Sedation in the Intensive Care Unit,” Anaesthesia, Vol. 54, No. 12, 1999, pp. 1136-1142.
[19] N. R. Villela, P. do Nascimento Junior, L. R. de Carvalho and A. Teixeira, “Effects of Dexmedetomidine on Renal System and on Vasopressin Plasma Levels. Experimental Study in Dogs,” Revista Brasileira de Anestesiologia, Vol. 55, No. 4, 2005, pp. 429-440.
[20] D. L. Herr, S. T. Sum-Ping and M. England, “ICU Sedation after Coronary Artery Bypass Graft Surgery: Dexmedetomidine-Based versus Propofol-Based Sedation Regimens,” Journal of Cardiothoracic and Vascular Anesthesia, Vol. 17, No. 5, 2003, pp. 576-584.
[21] M. Sorbellini, M. W. Kattan, M. E. Snyder, A. A. Hakimi, D. M. Sarasohn and P. Russo, “Prognostic Nomogram for Renal Insufficiency after Radical or Partial Nephrectomy,” Journal of Urology, Vol. 176, No. 2, 2006, pp. 472-476.
[22] A. M. De Wolf, R. J. Fragen, M. J. Avram, P. C. Fitzgerald and F. Rahimi-Danesh, “The Pharmacokinetics of Dexmedetomidine in Volunteers with Severe Renal Impairment,” Anesthesia & Analgesia, Vol. 93, No. 5, 2001, pp. 1205-1209.
[23] H. Xu, M. Aibiki, K. Seki, S. Ogura and K. Ogli, “Effects of Dexmedetomidine, an Alpha2-Adrenoceptor agonist, on Renal Sympathetic Nerve Activity, Blood Pressure, Heart Rate and Central Venous Pressure in Urethane-Anesthetized Rabbits,” Journal of the Autonomic Nervous System, Vol. 71, No. 1, 1998, pp. 48-54.
[24] P. J. Kulka, M. Tryba and M. Zenz, “Preoperative Alpha2-Adrenergic Receptor Agonists Prevent the Deterioration of Renal Function after Cardiac Surgery: Results of a Randomized, Controlled Trial,” Critical Care Medicine, Vol. 24, No. 6, 1996, pp. 947-952.
[25] V. R. Dharnidharka, C. Kwon and G. Stevens, “Serum Cystatin C Is Superior to Serum Creatinine as a Marker of Kidney Function: A Meta-Analysis,” American Journal of Kidney Diseases, Vol. 40, No. 2, 2002, pp. 221-226.
[26] S. Herget-Rosenthal, S. Trabold, J. Huesing, U. Heemann, T. Philipp and A. Kribben, “Cystatin C—An Accurate Marker of Glomerular Filtration Rate after Renal Trans-plantation?” Transplant International, Vol. 13, No. 4, 2000, pp. 285-289.
[27] M. Kleber, M. Cybulla, K. Bauchmuller, G. Ihorst, B. Koch and M. Engelhardt, “Monitoring of Renal Function in Cancer Patients: An Ongoing Challenge for Clinical Practice,” Annals of Oncology, Vol. 18, No. 5, 2007, pp. 950-958.
[28] A. Ahlstrom, M. Tallgren, S. Peltonen and V. Pettila, “Evolution and Predictive Power of Serum Cystatin C in Acute Renal Failure,” Clinical Nephrology, Vol. 62, No. 5, 2004, pp. 344-350.
[29] K. Dere, I. Sucullu, E. T. Budak, S. Yeyen, A. I. Filiz, S. Ozkan and G. Dagli, “A Comparison of Dexmedetomidine versus Midazolam for Sedation, Pain and Hemodynamic Control, during Colonoscopy under Conscious Sedation,” European Journal of Anaesthesiology, Vol. 27, No. 7, 2010, pp. 648-652.
[30] J. B. Dyck, M. Maze, C. Haack, L. Vuorilehto and S. L. Shafer, “The Pharmacokinetics and Hemodynamic Effects of Intravenous and Intramuscular Dexmedetomidine Hydrochloride in Adult Human Volunteers,” Anesthesiology, Vol. 78, No. 5, 1993, pp. 813-820.
[31] R. L. Mehta, J. A. Kellum, S. V. Shah, B. A. Molitoris, C. Ronco, D. G. Warnock and A. Levin, “Acute Kidney Injury Network: Report of an Initiative to Improve Outcomes in Acute Kidney Injury,” Critical Care, Vol. 11, No. 2, 2007, p. R31.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.